Evogene (EVGN) to Release Quarterly Earnings on Wednesday

Evogene (NASDAQ:EVGN) is expected to post its Q1 2025 quarterly earnings results before the market opens on Wednesday, May 21st. Analysts expect Evogene to post earnings of ($0.51) per share and revenue of $4.42 million for the quarter.

Evogene (NASDAQ:EVGN) last issued its earnings results on Thursday, March 6th. The biotechnology company reported $0.06 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.78. Evogene had a negative net margin of 314.43% and a negative return on equity of 109.05%. The firm had revenue of $1.61 million during the quarter, compared to analyst estimates of $3.63 million. During the same quarter in the prior year, the business earned ($1.30) earnings per share.

Evogene Stock Performance

Shares of NASDAQ:EVGN opened at $1.31 on Monday. The firm has a fifty day moving average price of $1.20 and a 200 day moving average price of $1.45. Evogene has a fifty-two week low of $0.95 and a fifty-two week high of $9.00. The firm has a market cap of $7.03 million, a price-to-earnings ratio of -0.29 and a beta of 1.55.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on EVGN shares. StockNews.com started coverage on shares of Evogene in a research note on Tuesday, May 13th. They set a “sell” rating on the stock. Alliance Global Partners reaffirmed a “buy” rating on shares of Evogene in a research note on Friday, March 7th.

Evogene Company Profile

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.